The government renewed its commitment to bolstering electricity system reliability to prevent recurrence of recent outages in ...
Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability ...
Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...
Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...
Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results